Stay updated on T-DM1 & Tucatinib in HER2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the T-DM1 & Tucatinib in HER2+ Breast Cancer Clinical Trial page.

Latest updates to the T-DM1 & Tucatinib in HER2+ Breast Cancer Clinical Trial page
- Check4 days agoChange DetectedThe page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.SummaryDifference1.0%
- Check11 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to January 13, 2025.SummaryDifference1.0%
- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check47 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check69 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference5%
- Check76 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.3%
- Check90 days agoChange DetectedThe article on the CompassHER2 RD Trial comparing T-DM1 and Tucatinib has been updated to a new version (v2.14.1) and is set for release on January 13, 2025, replacing the previous version (v2.14.0) from August 2, 2024.SummaryDifference2%
Stay in the know with updates to T-DM1 & Tucatinib in HER2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the T-DM1 & Tucatinib in HER2+ Breast Cancer Clinical Trial page.